Deep Insight — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Scala Bioscala-bio.cominSeries A · Mar 2026 · $16M
Scala Biodesign develops computational protein design software (ScalaOS) that combines atomistic modeling, evolutionary data, and AI to optimize enzymes, antibodies, therapeutic proteins, and antigens in a single design round.
AI & Machine LearningBiotechDeep Tech
Ravit Netzer(Co-founder & CEO)Adi Goldenzweig(Co-founder & CTO)Sarel Fleishman(Chief Scientist)
Co-investorsIT-Farm CorporationTLV Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.